



MOTHER & CHILD
GROUP OF COMPANIES

MDMG OPENS FIRST LAB FOR COLLECTION OF ANALYZES

10 December 2021 – MD Medical Group Investments Plc (“MD Medical Group”, “MDMG” or the “Company” – LSE, MOEX: MDMG), a leading Russian private healthcare provider, today announces the opening of its first lab for collection of analyzes.

It will operate under the special “MD LAB” brand in the North-Eastern Administrative District of Moscow.

The surface of the new lab is around 80 meters. It is fully equipped with modern equipment that allows to provide patients with a wide range of analyzes. All analyzes will be processed in the multifunctional laboratory that was opened in the “Lapino-2” hospital and possesses huge diagnostic resources.

It is expected that in the future several similar labs will be opened in different districts of Moscow and the Moscow region. Thus, the Company will continue to expand its presence in highly populated areas with steady consumer demand.

Mark Kurtser, CEO of MD Medical Group, said:

“By opening our first stand-alone laboratory, the Company begins to operate a new format of medical centers. These mini-laboratories will provide a new type of service for our patients, facilitating access to the services of the “Mother and Child” medical centers and contributing to the expansion of the Company’s client base”.

Sergey Arabadzhyan, Medical Director for Innovative Technologies of MD Medical Group, said:

“MD LAB” centers will increase patient loyalty, giving them the opportunity to appreciate all the benefits of medical services provided by the “Mother and Child” Group of companies. The initial regions for the new format will be Moscow and the Moscow Region where transport accessibility plays a huge role”.

This announcement contains inside information.

For further information please contact:

Investors

Dmitry Yakushkin

MD Medical Group Investments Plc

tel.: +7 (495) 139-87-40, ext. 16329

d.yakushkin@mcclinics.ru

Media

EM

Tom Blackwell: +7 919 102 9064

Sergii Pershyn: +1 929 855 8188

MDMG@em-comms.com

About MD Medical Group

MD Medical Group is a leading provider in the highly attractive Russian private healthcare service market. The company manages 43 modern healthcare facilities, including 6 hospitals and 37 out-patient clinics in Moscow and the Moscow Region, St. Petersburg, Ufa, Perm, Samara and the Samara Region, Novosibirsk, Irkutsk, Yaroslavl, Ryazan, Kostroma, Novokuznetsk, Krasnoyarsk, Omsk, Barnaul, Vladimir, Tyumen, Voronezh, Nizhny Novgorod, Volgograd, Tula, Kazan, Vladivostok, Krasnodar and Rostov-on-Don.

The Company's shares have been listed on the London Stock Exchange (LSE ticker "MDMG") in the form of Global Depositary Receipts (GDRs) since 12 October 2012.

Since 9 November 2020, the Company's GDRs are traded also on the Moscow Exchange. Quotation is done in Russian Rubles.

Forward-Looking Statements:

This press release contains forward looking statements, which are based on the Company's current expectations and assumptions and may involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. The forward looking statements contained in this press release are based on past trends or activities and should not be taken that such trends or activities will continue in the future. It is believed that the expectations reflected in these statements are reasonable, but they may be affected by a number of variables which could cause actual results or trends to differ materially, including, but not limited to: conditions in the market, market position of the Company, earnings, financial position, cash flows, return on capital and operating margins, anticipated investments and economic conditions; the Company's ability to obtain capital/additional finance; a reduction in demand by customers; an increase in competition; an unexpected decline in revenue or profitability; legislative, fiscal and regulatory developments, including, but not limited to, changes in environmental and health and safety regulations; exchange rate fluctuations; retention of senior management; the maintenance of labour relations; fluctuations in the cost of input costs; and operating and financial restrictions as a result of financing arrangements.

No statement in this press release is intended to constitute a profit forecast, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for the Company. Each forward looking statement relates only as of the date of the particular statement.